Stada Launches Medical Cannabis Portfolio
Company Introduces CannabiStada Range Of Flowers And Whole Extracts
Stada has announced the launch of its medical cannabis portfolio under the brand CannabiStada in Germany. The company will be rolling out both flowers and whole extracts, primarily geared towards chronic pain patients for whom established medications, such as opioids, do not work.
You may also be interested in...
Stada enjoyed double-digit growth for revenues and profitability when adjusted for currency and one-time costs last year, as the privately-owned German firm championed its supply chain investments amid the coronavirus pandemic.
Stada's Britannia Pharmaceuticals has acquired Sweden's Lobsor and its Lecigon gel formulation which is already approved in the Nordics and combines levodopa, carbidopa and entacapone infused via a lightweight pump. Meanwhile, Stada has also formed an alliance with MediPharm Labs for medical cannabis.
CNS specialist Neuraxpharm has struck a deal with Israel’s Panaxia to market medical cannabis products in Europe, starting in Germany.